Trastuzumab improves survival for HER2-positive breast cancer

the ONA take:

According to a recent study published in the Journal of Clinical Oncology, researchers performed a joint analysis of two trials comparing chemotherapy with and without trastuzumab and found that trastuzumab improved overall survival in patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Across the two studies, over 4,000 patients with node-positive HER2-positive breast cancer were randomly assigned to receive doxorubicin and cyclophosphamide, followed by paclitaxel with or without trastuzumab.

Results showed that the 10-year overall survival was 84% for those who received trastuzumab compared with 75% for those who did not. In addition, the 10-year disease-free survival was 74% for those that received trastuzumab versus 62% for who that did not receive the anti-HER2 monoclonal antibody.

In addition, the incidence of cardiotoxicity was observed in 3% of patients that received trastuzumab and most patients who experienced cardiac adverse effects recovered.

The early results of the same studies in this joint analysis lead to the approval of trastuzumab for the adjuvant treatment of HER2-positive breast cancers by the U.S. Food and Drug Administration in 2006. Now, after 10 years, the results show that the addition of trastuzumab improves overall survival and disease-free survival.

Trastuzumab improves survival for HER2-positive breast cancer
Trastuzumab improved overall survival in early-stage HER2-positive breast cancer.
The study, published in the Journal of Clinical Oncology, analyzed data from two independent trials designed to examine overall survival of patients with early-stage HER2-positive breast cancer who received chemotherapy with and without Herceptin.
READ FULL ARTICLE From Medical News Today
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs